Molecular alterations in the TCR signaling pathway in patients with aplastic anemia by unknown
RESEARCH Open Access
Molecular alterations in the TCR signaling
pathway in patients with aplastic anemia
Bo Li1*†, Lixing Guo1†, Yuping Zhang2, Yankai Xiao3, Mingjuan Wu1,3, Lingling Zhou3, Shaohua Chen1, Lijian Yang1,
Xiang Lu4 and Yangqiu Li1,3,5*
Abstract
Background: A previous study has demonstrated a significantly increased CD3ζ gene expression level in aplastic
anemia (AA). However, the mechanism underlying the upregulated CD3ζ mRNA expression level and that of T cell
activation signaling molecules in AA patients remains unclear. Thus, we investigated the expression levels of the
CD3ζ, CD28, CTLA-4, and Cbl-b genes, the SNP rs231775 in the CTLA-4 gene, and the distribution of the CD3ζ 3′-
UTR splice variant in AA patients.
Methods: CD3ζ 3′-UTR splice variants were identified in peripheral blood mononuclear cells (PBMCs) from 48
healthy individuals and 67 patients with AA [37 cases of severe aplastic anemia (SAA) and 30 cases of non-sever
aplastic anemia (NSAA)] by RT-PCR. CD3ζ, CD28, CTLA-4, and Cbl-b gene expression was analyzed by real-time
quantitative PCR. The SNP rs231775 in CTLA-4 gene was analyzed by PCR-RFLP.
Results: CD3ζ and CD28 expression was significantly higher, while CTLA-4 and Cbl-b expression was significantly
lower in AA patients compared with healthy individuals. Significantly higher CD3ζ expression was found in the
NSAA subgroup compared with the SAA subgroup. 64 % of the AA samples had the same genotype (WT+AS+CD3ζ
3′-UTR); 22 % of the AA patients had a WT+AS−CD3ζ 3′-UTR genotype, and 14 % of the AA patients had a WT−AS
+CD3ζ 3′-UTR genotype. The CD3ζ expression level of WT−AS+ subgroup was the highest in the SAA patients. A
significantly higher frequency of the GG genotype (mutant type, homozygous) of SNP rs231775 in CTLA-4 gene was
found in the AA patients. Positive correlation between the CTLA-4 and Cbl-b gene expression levels was found in
healthy individuals with the AA and AG genotypes, but not in the AA patients.
Conclusions: This is the first study analyzing the expression characteristics of the CD28, CTLA-4, and Cbl-b genes in
AA. Our results suggest that aberrant T cell activation may be related to the first and second signals of T cell
activation in AA. The GG genotype of SNP rs231775 in CTLA-4 gene might be associated with AA risk in the
Chinese population. The characteristics of CD3ζ 3′-UTR alternative splicing may be an index for evaluating the T cell
activation status in AA patients, particularly in SAA patients.
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Background
Aplastic anemia (AA) is a serious hematological disorder
characterized by pancytopenia [1–3]. AA is an immune-
mediated destruction of hematopoietic cells caused by
abnormally activated T cells for most cases [4, 5]. Our pre-
vious study has shown that, in addition to abnormal distri-
bution and clonal expansion of the T cell receptor (TCR)
repertoire, there is significantly higher CD3ζ expression in
T cells in AA patients [6]. An abnormal CD3ζ gene expres-
sion level may directly represent a characteristic of abnor-
mal T cell activation.
T cell recognition of antigenic peptide/major histocom-
patibility complexes plays a pivotal role in the initiation
and regulation of the adaptive immune response [7–9].
TCR activation plays a crucial role in T cell function. The
TCR itself does not possess signaling domains. Instead,
the TCR is non-covalently coupled to a conserved multi-
subunit signaling apparatus, i.e., the CD3 complex, which
comprises the CD3εγ, CD3εδ, and CD3ζζ dimmers [10].
However, the TCR/CD3 signaling complex alone is insuffi-
cient for antigen-specific T cell responses and a second
pathway, co-stimulatory signaling, is required for T cell
immune responses. The co-stimulatory signaling molecule
CD28 that is found on T cells must bind B7-1 and B7-2,
which are expressed on antigen presenting cells (APCs),
to trigger T cell activation [11, 12]. Upon T cell activation,
cytotoxic T-lymphocyte antigen-4 (CTLA-4) is induced
and outcompetes CD28 for B7-1 and B7-2 ligands, thereby
preventing excessive T cell expansion [13, 14]. This
mechanism provides a key checkpoint in the regulation
of T cell immunity [15, 16]. The SNP rs231775, A > G
transition mutation which is located at exon 1 in the
CTLA-4 gene, has been reported to potentially influ-
ence the inhibitory function of CTLA-4 by reducing its
cell surface expression [17, 18].
Optimal T cell activation requires signaling through the
TCR and the CD28 co-stimulatory receptor. CD28 co-
stimulation is believed to set the threshold for T cell acti-
vation. Casitas B-lineage lymphoma proto-oncogene-b
(Cbl-b), a RING finger E3 ubiquitin-protein ligase, is in-
volved in CD28-dependent T cell activation [19]. Results
from T cell activation assays in vitro have shown that
CD28 co-stimulation promotes TCR-induced Cbl-b deg-
radation, whereas CTLA-4-B7 interaction potentiates
TCR-induced Cbl-b re-expression [20].
Expression of the CD3ζ gene is regulated at the
transcriptional, posttranscriptional, and posttranslational
levels [21]. As previously described, there are two isoforms
of the CD3ζ 3′-UTR: a wild type (WT) isoform (906 bp)
and an alternatively spliced (AS) isoform (344 bp). Abnor-
mal CD3ζ expression was found in T cell from SLE pa-
tients, and this may be associated with decreased stability
and translation of CD3ζ mRNAs that contain AS CD3ζ
3′-UTRs [22]. However, the mechanism of upregulating
the CD3ζ mRNA expression level in AA patients is
unclear.
Thus, we investigated the expression level of the
CD28, CTLA-4, Cbl-b, and CD3ζ genes, the SNP
rs231775 in CTLA-4 gene, CD3ζ-regulating factors, and
the distribution of the CD3ζ 3′-UTR splice variant. We
concluded that analysis of these factors may facilitate
the comprehensive understanding of the abnormal T
cell immune characteristics of AA.
Results
The expression levels of CD3ζ, CD28, CTLA-4, and Cbl-b in AA
The expression levels of the CD3ζ, CD28, CTLA-4, and
Cbl-b genes in cDNA from PBMCs from 67 AA patients
before treatment and 48 healthy individuals were quanti-
tatively assessed by real-time polymerase chain reaction
(PCR) using the SYBR Green I technique. The results
demonstrated an increased expression level for CD28
(median 0.75) and CD3ζ (median 1.27) in AA patients
compared with healthy individuals (CD28 0.49, P < 0.01;
CD3ζ 0.95, P < 0.05; Fig. 1), while significantly decreased
CTLA-4 (median 0.13) and Cbl-b (median 0.27) expres-
sion was found (CTLA-4 0.18, P < 0.01; Cbl-b 0.55, P <
0.01; Fig. 1). Significantly increased CD3ζ expression (me-
dian: 0.13) was found in the non-severe aplastic anemia
patients (NSAA) compared with sever aplastic anemia
patients (SAA, median: 0.18, P < 0.05). There were no
significant differences in CD28, CTLA-4, and Cbl-b
expression between the SAA and NSAA groups (Fig. 2).
The expression characteristics of the CD3ζ gene with
different CD3ζ 3′-UTR isoforms in AA
Two types of CD3ζ 3′-UTR splicing variants, WT and AS
CD3ζ 3′-UTR, were detected in all of the healthy indi-
viduals. However, a significantly lower frequency of the
WT+AS+CD3ζ 3′-UTR genotype was detected in the AA
patients (43 cases, P < 0.01), and a significantly higher
frequency of the WT+AS-CD3ζ 3′-UTR (15 cases,
P < 0.01) and WT−AS+CD3ζ 3′-UTR (9 cases, P < 0.01)
genotypes were detected in the AA patients (Fig. 3a).
There were no significant differences in the frequencies of
the three types of CD3ζ 3′-UTR between the SAA and
NSAA patients although the frequency of the WT-AS
+CD3ζ 3′-UTR was high in the SAA patients (19 %)
compared with that of the NSAA patients (7 %), while the
WT+AS+CD3ζ 3′-UTR frequency was low in the SAA
patients (57 %) compared with that of the NSAA patients
(73 %).
Based on the CD3ζ 3′-UTR isoform expression, we
divided the 67 AA cases into three subgroups: WT+AS+,
WT+AS− and WT−AS+. There were no significant differ-
ences in the CD3ζ expression among the three sub-
groups. To better comprehend the difference in the
CD3ζ expression level between the SAA and NSAA
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patients, we compared the CD3ζ expression level in the
WT+AS+, WT+AS−, and WT−AS+ subgroups in the SAA
and NSAA patients. A significantly increased CD3ζ ex-
pression level (median 1.46) was found in the WT−AS+
subgroup compared with the WT+AS+ (median 0.78, P
< 0.05) and WT+AS− subgroups (median 0.45, P = 0.06)
in the SAA patients. However, there were no significant
differences in the CD3ζ expression level among the three
subgroups in the NSAA patients (Fig. 3b).
The genotype frequency for SNP rs231775 in CTLA-4 gene
in AA
The genotype distribution for SNP rs231775 in CTLA-4
gene in the AA patients (67 cases) and healthy individ-
uals (84 cases) is shown in Fig. 4a, b. Gel electrophoresis
results from TseI digests and the sequences of the differ-
ent genotypes of SNP rs231775 in CTLA-4 gene are
shown in Fig. 4c–f. AA patients had a borderline signifi-
cantly higher frequency of the GG homozygous genotype
compared with healthy individuals (46 % vs. 31 %, OR =
1.92, 95 % CI = 0.99–3.74, P = 0.05). AA patients had a
significantly higher frequency of the G allele of SNP
rs231775 in CTLA-4 gene compared with healthy
individuals (60 % vs. 48 %, OR = 0.61; 95 % CI = 0.39–
0.97, P = 0.03). Analysis of the AA patients with the dif-
ferent genotypes for correlations with clinical parameters
including age of onset, gender, severity of AA, and
laboratory parameters was performed. However, no clin-
ical or laboratory parameters were found to have a sig-
nificant association with different genotypes of SNP
rs231775 in CTLA-4 gene. In addition, the CTLA-4
expression level in the AA patients and healthy individ-
uals had no significant association with the genotypes
of SNP rs231775 in CTLA-4 gene.
Correlation of the relative expression of CTLA-4 and
Cbl-b in AA
It has been reported that CTLA-4 regulates Cbl-b at the
transcriptional level. We next estimated the correlation
between the CTLA-4 and Cbl-b gene expression levels
in AA patients and healthy individuals. There was a sig-
nificant correlation between the expression levels of the
CTLA-4 and Cbl-b genes in healthy individuals with the
AA (rs = 0.59, P = 0.02) and AG (rs = 0.58, P = 0.03)
genotypes, while there was no significant correlation be-
tween the expression levels of the CTLA-4 and Cbl-b
Fig. 1 The relative gene expression levels of the CD3ζ, CD28, CTLA-4, and Cbl-b in AA and HIs. a The relative gene expression levels of CD3ζ in AA
and HIs; b the relative gene expression levels of CD28 in AA and HIs; c the relative gene expression levels of CTLA-4 in AA and HIs; d the relative gene
expression levels of Cl-b in AA and HIs
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genes (rs = −0.09, P = 0.71) in healthy individuals with
the GG genotype (Fig. 5). In all of the patients with
the various genotypes, there was no significant correl-
ation between the expression levels of the CTLA-4
and Cbl-b genes.
Discussion
AA is an immune-mediated disease in which T cell tar-
get hematopoietic cells [23, 24]. The precise mechanism
of T cell activation in AA pathogenesis remains un-
known. TCR signaling plays an important role in T cell
Fig. 2 The relative gene expression levels of CD3ζ, CD28, CTLA-4, and Cbl-b in SAA and NSAA. a The relative gene expression levels of CD3ζ in
SAA and NSAA; b the relative gene expression levels of CD28 in SAA and NSAA; c the relative gene expression levels of CTLA-4 in SAA and NSAA;
d the relative gene expression levels of Cbl-b in SAA and NSAA
Fig. 3 CD3ζ 3′-UTR splicing variant isoforms in AA and HIs. a The WT and AS isoforms could be detected in all of the healthy individuals (lane 1),
64 % of the AA patients contained WT+AS+CD3ζ 3′-UTR (lane 2), 22 % of the AA patients had only the WT+AS−CD3ζ 3′-UTR (lanes 4 and 5), and
14 % of the AA patients had only the WT-AS+CD3ζ 3′-UTR (lanes 6 and 7). Lane 3 is a 100 bp DNA ladder; b the expression level of the CD3ζ
gene with different CD3ζ 3′-UTR splicing variant isoforms in SAA
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activation [25, 26]. In this study, we analyzed the expres-
sion of TCR signaling molecules and related factors that
are involved in mediating TCR signaling in AA patients.
T cell activation requires the delivery of at least two
signals. The first signal is antigen-specific and MHC-
TCR ligation, and the second is a co-stimulatory signal
[13, 27, 28]. Co-stimulatory signals occur via the binding
of CD28, which is located on T cell, with B7 family mem-
bers on APCs. Initial activation of T cell after antigen ex-
posure is mediated by the CD28/B7 interaction and leads
to the proliferation and differentiation of effector T cell
[29]. Co-stimulation cannot proceed unchecked; other-
wise, an overwhelming immune response will ultimately
ruin the host. The co-stimulatory system consists of
peculiar mechanisms that can dampen T cell activation
signals, resulting in immune homeostasis. CTLA-4, an in-
hibitory signaling molecule that prevents T cell activation,
becomes expressed on activated T cell when T cell activa-
tion has reached its peak [30, 31]. CD28 and CTLA-4 con-
trol the threshold for T cell activation by regulating the
level of Cbl-b expression [19, 20].
In this study, we analyzed the expression characteris-
tics of the CD3ζ, CD28, CTLA-4, and Cbl-b genes, and
our data indicate significantly decreased CTLA-4 and
Cbl-b and increased CD3ζ and CD28 expression in AA
patients. These results suggest that there may be aber-
rant T cell activation, which may be related to the first
and second signals of the T cell activation signaling
Fig. 4 The genotype characteristic of SNP rs231775 in CTLA-4 gene in AA and HIs. a Distribution of the genotype of SNP rs231775 in AA patients
(n = 67); b distribution of the genotype of SNP rs231775 in HIs (n = 84); c agarose gel electrophoresis results for SNP rs231775 in CTLA-4 gene, lane
1 is the AG genotype, lane 2 is the GG genotype, lane 3 is a 50 bp DNA ladder, lane 4 is the AA genotype, and lane 5 is a PCR product without
TseI digestion; d sequencing results of AA genotype; e sequencing results of AG genotype; f sequencing results of GG genotype; the red arrow
indicates the single-nucleotide polymorphism sites
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molecules in AA. However, do the other signaling mole-
cules of TCR signaling such as CD3γ, CD3δ, CD3ε, and
ZAP-70 [32, 33] also have similar change trend in AA, it
is needed further investigation, and it is suggested to
characterize the alteration of gene expression profile.
Downregulated Cbl-b gene expression in AA suggests
that the threshold for T cell activation is different from
that in healthy individuals. There is variation in the CD3
gene expression level in SAA and NSAA patients, which
indicates that an aberrant T cell activation is more obvi-
ous in NSAA patients and may help distinguish between
SAA and NSAA patients for immunosuppressive treat-
ments in the clinic.
It is known that CD3ζ is the key regulator of the TCR/
CD3 complex in T cell activation [34, 35]. The increased
CD3ζ expression in AA samples indicated abnormal T
cell activation at least in some subsets of T cell in the
patients, while a differently significant CD3ζ gene ex-
pression pattern was found for SAA and NSAA in this
study. However, the underlying mechanism remains un-
clear because a previous study showed that different dis-
tributions of the CD3ζ 3′-UTR isoforms may affect
CD3ζ and its related gene expression. Therefore, we
compared the CD3ζ expression characteristics in sub-
groups containing different combinations of the CD3ζ
3′-UTR isoforms.
In general, the WT and AS 3′-UTR play different roles
in CD3ζ transcript stability and generation of the CD3ζ
protein [36]. In this study, we first characterized the dis-
tribution of the WT and AS 3′-UTRs in AA patients.
Interestingly, we found that only 64 % of the AA sam-
ples expressed WT+AS+CD3ζ 3′-UTR, which was
thought to be the normal genotype. We also found two
different subgroups, WT+AS−CD3ζ 3′-UTR (22 %) and
WT−AS+CD3ζ 3′-UTR (14 %), in the AA patients, which
may be related to the change in the CD3ζ level in the
patients. Because we could not find a difference in the
CD3ζ expression level in the total AA samples, we
further compared the SAA and NSAA groups. Not-
ably, an increased CD3ζ expression level was found in
the WT−AS+ CD3ζ 3′-UTR SAA group compared
with both the WT+AS+ CD3ζ 3′-UTR and WT+AS−
CD3ζ 3′-UTR SAA groups. Interestingly, there was
no significant difference in the CD3ζ expression level
Fig. 5 Correlation analysis of the CTLA-4 and Cbl-b expression levels for different genotypes of SNP rs231775 in CTLA-4 gene in AA and HIs. a CTLA-4
and Cbl-b in AA with the AA genotype, b CTLA-4 and Cbl-b in AA with the AG genotype, c CTLA-4 and Cbl-b in AA with the GG genotype, d CTLA-4
and Cbl-b in HIs with the AA genotype, e CTLA-4 and Cbl-b in HIs with the AG genotype, and f CTLA-4 and Cbl-b in HIs with the GG genotype
Li et al. Journal of Hematology & Oncology  (2016) 9:32 Page 6 of 9
between the WT+AS+, WT−AS+, and WT+AS− subgroups
for the NSAA patients. Therefore, there may be a differ-
ence in the regulation of the CD3ζ expression level and T
cell activation between SAA and NSAA. At a minimum, it
is thought that the CD3ζ 3′-UTR isoforms may influence
the CD3ζ expression level in T cells from SAA, which may
be one reason for the abnormal T cell activation.
It has been reported that aberrant CD3ζ expression
may be associated with the decreased stability and trans-
lation of CD3ζ mRNAs with an AS CD3ζ 3′-UTR in
SLE [22, 36]. In this study, the CD3ζ gene expression
level in some SAA patients was thought to be affected
by different splicing variants of the CD3ζ 3′-UTR. As
our results demonstrated, there was an increased CD3ζ
expression level in SAA patients with the WT-AS+ CD3ζ
3′-UTR genotype, and whether this is feedback regula-
tion remains an open question. The T cell activation
function in SAA patients will be examined in the future
to evaluate the influence of the CD3ζ 3′-UTR isoforms.
To characterize the positive and negative regulatory fac-
tors of the TCR signal pathway, it is necessary to analyze
the characteristics of the negative factors e.g., CTLA-4
and Cbl-b. It has been reported that SNP rs231775 in
CTLA-4 gene is associated with an increased frequency
of autoimmune diseases such as Graves’ disease, auto-
immune hypothyroidism, type I diabetes, and multiple
sclerosis [37–39]. ]s To determine whether this SNP also
plays a role in AA, we analyzed its distribution in AA
samples. To our knowledge, this is the first study to
analyze this SNP in Chinese AA patients. Interestingly,
we found that the homozygous GG mutant was signifi-
cantly higher in AA patients, indicating that this CTLA-
4 variant may have an association with susceptibility to
developing AA. However, this result is in contrast with a
report by Svahn J et al. who demonstrated that there
were no significant differences in the genotype or allele
frequency of SNP rs231775 in CTLA-4 gene between
AA patients and healthy individuals in the Caucasian
population [40]. However, the CTLA-4 mRNA expres-
sion level had no significant association with the geno-
type of SNP rs231775 in CTLA-4 gene in this study
because SNP rs231775 is associated with the protein
level [17, 18]. Further study is needed to analyze the
CTLA-4 protein level in T cell from AA patients to con-
firm this result.
CTLA-4 regulates TCR signals via Cbl-b, and it plays
an important role in regulating it at the transcriptional
level [20]. However, little is known about the mRNA ex-
pression pattern of CTLA-4 and Cbl-b in AA patients.
In this study, we found a significant positive correlation
between CTLA-4 and Cbl-b in healthy individuals with
the AA and AG genotypes of SNP rs231775 in CTLA-4
gene but not in those with the GG genotype of SNP
rs231775 in CTLA-4 gene. However, there was no
significant correlation between CTLA-4 and Cbl-b in
any of the patients. These results indicate that CTLA-4
loses its proper regulatory role of Cbl-b expression at
the transcriptional level in AA patients.
Conclusion
In conclusion, this is the first study to analyze the
expression characteristics of the CD28, CTLA-4, and
Cbl-b genes, the distribution of the CD3ζ 3′-UTR splice
variant in AA patients, and the SNP rs231775 in CTLA-
4 gene in Chinese AA patients. We found that aberrant
T cell activation may be associated with either the first
or second T cell activation signaling molecules in AA.
Different CD3ζ expression patterns in SAA and NSAA
patients suggest different abnormal alternative CD3ζ
pathway patterns in SAA and NSAA patients. The
mutant type homozygous GG and G allele for SNP
rs231775 in CTLA-4 gene might be associated with AA
risk for the Chinese population.
Methods
Samples
The AA group consisted of 67 patients with newly diag-
nosed AA (36 cases with SAA and 31 with NSAA, in-
cluding 37 males and 30 females; median age 34 years,
range 9–78 years). The information and clinical data of
the patients are described in Table 1. Forty-eight healthy
individuals (21 males and 27 females; median age
35.5 years, range 20–80 years) were used for detecting
CD3ζ, CD28, CTLA-4, and Cbl-b genes expression levels
and CD3ζ 3′-UTR isoform, and 84 healthy individuals
(40 males and 44 females; median age 33 years, range 6–
88 years) were used for detecting for SNP rs231775 in
CTLA-4 gene. AA diagnoses were established by bone
marrow biopsy and peripheral blood counts. All of the
Table 1 The demographic and clinical characteristics of AA
patients
Patients characteristics (n = 67) No. (%)









Hb (g/L) Median 65.0
ANC (109/L) Median 0.38
PLT (109/L) Median 11.5
Hb hemoglobin, ANC absolute neutrophil count, PLT platelet
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procedures were performed according to the guidelines
of the Medical Ethics committee of the health bureau of
the Guangdong Province of China. Peripheral blood
mononuclear cell (PBMC) isolation, RNA and DNA ex-
traction, and cDNA synthesis were performed according
to the manufacturer’s instructions.
RT-PCR for CD3ζ 3′-UTR isoform
The primer specificity for CD3ζ 3′-UTR amplification
was as follows: forward 5′-CAGCCAGGGGATTTCAC-
CACTCAAAG-3′ reverse 5′-CCCTAGTACATTGACG
GGTTTTTCCTG-3′ [41]. The amplification was carried
out after initial denaturation at 94 °C for 4 min, 30 cycles
at 94 °C, 45 s; 67 °C, 1 min; 72 °C for 2 min; and a final
extension at 72 °C for 7 min. After completion of the
PCR, 20 μl of the PCR products were electrophoresed
on a 1.5 % agarose gel.
Real-time relative quantitative PCR for the CD3ζ, CD28,
CTLA-4, and Cbl-b genes
Real-time PCR using the SYBR Green I method [42, 43]
was used to examine the CD3ζ, CD28, CTLA-4, and
Cbl-b genes with cDNA obtained from the PBMCs of AA
patients and healthy individuals. The CD3ζ and β2M
primer sequences and PCR conditions were previously
described [26]. The other primer sequences were as
follows: CD28: 5′-GAAACACCTTTGTCCAA GTC-3′
and 5′-GGGGAGTCATGTTCATGTAG-3′, CTLA-4: 5′-
GTCAGCCTGCCGAAGC ACT-3′ and 5′-GTCAGCC
TGCCGAAGCACT-3′, and Cbl-b: 5′-CCCTGGAATTG
ACCATTGGG-3′ and 5′-ACTTGCCCAACTCAGTGA
GAA-3′. The real-time PCR reactions were performed in
a total volume of 25 μl containing approximately 1 μl
cDNA, 0.5 μM of each primer pair, and 11.25 μl 2.5×
RealMasterMix (Tiangen, Beijing). After an initial de-
naturation at 95 °C for 15 min, 40 cycles of the following
procedure were performed using an MJ Research DNA
Engine Opticon 2 PCR cycler (BIO-RAD, Hercules, CA,
USA): 15 s at 95 °C and 30 s at 60 °C followed by 1 s at
80 °C for plate reading. The 2(–ΔCT) method was used to
analyze the genes of interest relative to an internal control
gene.
Polymerase chain reaction and restriction fragment
length polymorphism (RFLP)
The SNP rs231775 in CTLA-4 gene exon 1 were ampli-
fied using the following primers: 5′-CACATGTGTAA-
TACATATCTGGG-3′ and 5′-TTGCAGAAGACAGGG
ATG AAGA-3′. The polymerase chain reaction (PCR)
mixture contained 100 ng of genomic DNA, 0.1 mM
each of deoxynucleotide triphosphates, 12.5 pmol each
of the primers, and 1 U Taq polymerase (Applied Biosys-
tems, Foster City, CA, USA) in a 25 μl final volume. The
samples were heated at 95 °C for 2 min followed by
35 cycles of 94 °C for 60 s, 60 °C for 60 s, and 72 °C for
60 s with a final extension at 72 °C for 5 min. The PCR
products (50 μl) were digested overnight with the re-
striction enzyme TseI (NEB, UK) according to the man-
ufacturer’s protocol, and they were analyzed by 2.5 %
agarose gel electrophoresis. The digestion of PCR prod-
ucts in the presence of the restriction sites is indicative
of the presence of the G allele. The finding of a single
band of 250 bp is indicative of the AA genotype,
whereas the GG genotype is indicated by the finding of
two bands at 189 and 61 bp. On the other hand, the
AG genotype is characterized by the appearance of
three bands: one at 250 bp and the others at 189 and
61 bp. The different genotypes were successfully con-
firmed by DNA sequencing.
Statistical analysis
The Mann-Whitney test was performed to compare
each gene expression level between different groups.
Spearman correlation analyses were used to estimate
correlations between different gene expression levels.
Fisher’s exact test was used to compare genotypes or
allelic frequencies between different groups. A P < 0.05
was considered to be statistically significant.
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